TITLE:
Effect of Bromocriptine on Insulin Resistance in Patients with PCO
AUTHORS:
Zivar Shirinpour, Bahman Ghaderian, Homeira Rashidi, Armaghan Moravej Aleali, Seyed Peyman Payami
KEYWORDS:
Bromocriptine, Insulin Resistance, PCO, FBS
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.4 No.12,
December
29,
2014
ABSTRACT: Introduction: Poly
cystic ovary (PCO) is one of the most common endocrine disorders in women. All
patients with PCO are at risk of insulin resistance, IFG and diabetes.
Recently, bromocriptine is used in treatment of diabetes mellitus type II to
improve insulin resistance. Objective: The aim of this study is the evaluation
of bromocriptine on insulin resistance in PCO people. Patients and Methods: In
this single-blind controlled clinical trial with placebo, 44 patients with PCO
referring to endocrinology clinic were evaluated. Inclusion criteria were BMI >
25 kg/m2 and diagnosed PCO patients according to Rotterdam criteria
and rule out other causes. Blood samples were obtained for FBS, Fasting
Insulin, Prolactin, TSH and 17(OH)P. They divided two groups: Case group was
given bromocriptine 2.5 mg daily and placebo was given to control group. Patients
were treated for 8 days and in day 9th blood sample was obtained for FBS,
Fasting insulin, HOMA-IR index. Mann-Whitney method is used for mean
comparison. Results: Data analysis using showed in pre diabetes range, mean
changes of FBS, insulin level and IR in Groups 1 and 2 had significant differences(P
= 0.004), but no significant different was found in FBS 2, no significant differences
were found in changes in FBS 2, no significant
differences were found in changes in insulin level and IR (P = 0.69, 0.089
respectively). Mean systolic blood pressure changes in Group 1 and 2 in FBS
> 100 mg/dl with (P = 0.036) were significant, but no significant difference
showed in mean change of diastolic blood pressure in FBS > 100 mg/dl (P =
0.99). In FBS